Cargando…
Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era
With the markedly increased cure rate for children with newly diagnosed pediatric B-cell acute lymphoblastic leukemia (B-ALL), relapse and refractory B-ALL (R/R B-ALL) remain the primary cause of death worldwide due to the limitations of multidrug chemotherapy. As we now have a more profound underst...
Autores principales: | Mengxuan, Shang, Fen, Zhou, Runming, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259965/ https://www.ncbi.nlm.nih.gov/pubmed/35813376 http://dx.doi.org/10.3389/fped.2022.923419 |
Ejemplares similares
-
Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
por: Graiqevci-Uka, Violeta, et al.
Publicado: (2022) -
Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023) -
Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023) -
Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
por: Wu, Ying, et al.
Publicado: (2022) -
Epigenetic Modifications in Pediatric Acute Lymphoblastic Leukemia
por: Burke, Michael J., et al.
Publicado: (2014)